Table 3.
Summary of meta-analysis on the improvement of comorbidities with pasireotide.
| Clinical parameters | SMD | 95% CI | I² | Included studies (n) | Included patients (n) |
|---|---|---|---|---|---|
| BMI | -1.49 | -2.08, -0.90 | 81.4% | 5 | 381 |
| Randomized studies only | -1.44 | -2.07, -0.82 | 90.5% | 2 | 312 |
| Waist circumference | -3.54 | -4.84, -2.24 | 55% | 5 | 381 |
| Randomized studies only | -3.32 | -5.2, -1.43 | 77% | 2 | 312 |
| Systolic blood pressure | -6.30 | -8.46, -4.13 | 41.8% | 7 | 448 |
| Randomized studies only | -7.18 | -10.49, -3.87 | 51% | 2 | 312 |
| Diastolic blood pressure | -4.32 | -5.83, -3.01 | 0% | 6 | 432 |
| Randomized studies only | -3.95 | -5.8, -2.31 | 0% | 2 | 312 |
I2, Higgins test of heterogeneity; CI, confidence interval; PI, predictive interval; SMD, standard mean deviation.